¹⁷⁷Lu-PSMA-617 Improves Upon Enzalutamide in mCRPC
Adding the radionuclide therapy ¹⁷⁷Lu-PSMA-617 to enzalutamide improved outcomes in patients with treatment-naïve mCRPC in a phase 2 trial.
Adding the radionuclide therapy ¹⁷⁷Lu-PSMA-617 to enzalutamide improved outcomes in patients with treatment-naïve mCRPC in a phase 2 trial.
Petros Grivas, MD, PhD, discusses the significance of the phase 3 JAVELIN Bladder 100, EV-302, and CheckMate 901 trials in urothelial cancer.
Jonathan E. Rosenberg, MD, discusses ongoing and planned research efforts to enhance the frontline and beyond urothelial cancer treatment landscape.
The phase 3 KeyVibe-010 trial of adjuvant vibostolimab plus pembrolizumab in patients with resected high-risk melanoma has been discontinued.
An abstract is unavailable.
Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.
Asian Americans, Native Hawaiian, and Other Pacific Islanders
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Samilia Obeng-Gyasi, MD, MPH, expands on the impact of social determinants of health on breast cancer care.
Dry, scaly skin can be a sign of many common dermatologic issues, and sometimes even a sign of cancer. We checked with dermatologist Saira George,…
Supported by an independent educational grant from Genmab US, Inc. and AbbVie This live roundtable discussion will center on the advancing field of bispecific antibodies…